Effect of androgen deprivation therapy on muscle attenuation in men with prostate cancer

Chang, David, Joseph, David J., Ebert, Martin A., Galvao, Daniel A., Taaffe, Dennis R., Denham, James W., Newton, Robert U. and Spry, Nigel A. (2014) Effect of androgen deprivation therapy on muscle attenuation in men with prostate cancer. Journal of Medical Imaging and Radiation Oncology, 58 2: 223-228. doi:10.1111/1754-9485.12124


Author Chang, David
Joseph, David J.
Ebert, Martin A.
Galvao, Daniel A.
Taaffe, Dennis R.
Denham, James W.
Newton, Robert U.
Spry, Nigel A.
Title Effect of androgen deprivation therapy on muscle attenuation in men with prostate cancer
Journal name Journal of Medical Imaging and Radiation Oncology   Check publisher's open access policy
ISSN 1754-9485
1754-9477
Publication date 2014
Year available 2013
Sub-type Article (original research)
DOI 10.1111/1754-9485.12124
Open Access Status
Volume 58
Issue 2
Start page 223
End page 228
Total pages 6
Place of publication Richmond, VIC, Australia
Publisher Blackwell Publishing
Collection year 2014
Language eng
Formatted abstract
Introduction: Aging skeletal muscle is associated with not only a reduction in muscle size and strength but also in muscle quality which reflects an increase in fatty infiltration of muscle. In men with prostate cancer, androgen deprivation therapy (ADT) accelerates this loss of muscle size and strength, but it is unknown if muscle quality is also adversely affected. Therefore, we examined the effects of ADT on muscle attenuation, an indirect measure of intramuscular lipid content, as well as the muscle cross-sectional area (CSA) in men with prostate cancer.

Methods: Pre- and post-CT scans of the pelvis in 39 men aged 49-78 years receiving leuprorelin were examined. The time between baseline and follow-up scans was 14.6-20 weeks after the commencement of ADT. Changes in skeletal muscle attenuation in Hounsfield units of the rectus femoris and the CSA of the rectus femoris, sartorius and quadricep muscles were assessed.

Results: Muscle attenuation of the rectus femoris muscle was significantly reduced following the initiation of ADT by 18.9% (P < 0.001). In addition, there was a significant decrease (P < 0.001) in the CSA for the sartorius, quadriceps and rectus femoris muscles. There was no effect of Zometa on muscle attenuation or muscle CSA.

Conclusions: Our results indicate that not only muscle size but also muscle quality may be adversely affected by the undertaking of ADT in men with prostate cancer. Consequently, interventions to counteract deteriorations to both muscle mass and possibly muscle quality should be considered in men receiving ADT.
Keyword CT
Intramuscular fat
Myosteatosis
Sarcopenia
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2014 Collection
School of Human Movement and Nutrition Sciences Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 8 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 7 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 22 Apr 2014, 02:26:13 EST by System User on behalf of School of Human Movement and Nutrition Sciences